» Articles » PMID: 37591771

Generative Adversarial Network-Enhanced Ultra-Low-Dose [F]-PI-2620 τ PET/MRI in Aging and Neurodegenerative Populations

Overview
Specialty Neurology
Date 2023 Aug 17
PMID 37591771
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: With the utility of hybrid τ PET/MR imaging in the screening, diagnosis, and follow-up of individuals with neurodegenerative diseases, we investigated whether deep learning techniques can be used in enhancing ultra-low-dose [F]-PI-2620 τ PET/MR images to produce diagnostic-quality images.

Materials And Methods: Forty-four healthy aging participants and patients with neurodegenerative diseases were recruited for this study, and [F]-PI-2620 τ PET/MR data were simultaneously acquired. A generative adversarial network was trained to enhance ultra-low-dose τ images, which were reconstructed from a random sampling of 1/20 (approximately 5% of original count level) of the original full-dose data. MR images were also used as additional input channels. Region-based analyses as well as a reader study were conducted to assess the image quality of the enhanced images compared with their full-dose counterparts.

Results: The enhanced ultra-low-dose τ images showed apparent noise reduction compared with the ultra-low-dose images. The regional standard uptake value ratios showed that while, in general, there is an underestimation for both image types, especially in regions with higher uptake, when focusing on the healthy-but-amyloid-positive population (with relatively lower τ uptake), this bias was reduced in the enhanced ultra-low-dose images. The radiotracer uptake patterns in the enhanced images were read accurately compared with their full-dose counterparts.

Conclusions: The clinical readings of deep learning-enhanced ultra-low-dose τ PET images were consistent with those performed with full-dose imaging, suggesting the possibility of reducing the dose and enabling more frequent examinations for dementia monitoring.

Citing Articles

Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data.

Karlsson L, Vogel J, Arvidsson I, Astrom K, Strandberg O, Seidlitz J Alzheimers Dement. 2025; 21(2):e14600.

PMID: 39985487 PMC: 11846480. DOI: 10.1002/alz.14600.


A machine learning-based prediction of tau load and distribution in Alzheimer's disease using plasma, MRI and clinical variables.

Karlsson L, Vogel J, Arvidsson I, Astrom K, Strandberg O, Seidlitz J medRxiv. 2024; .

PMID: 38853877 PMC: 11160861. DOI: 10.1101/2024.05.31.24308264.


Current Trends and Applications of PET/MRI Hybrid Imaging in Neurodegenerative Diseases and Normal Aging.

Lee J, Renslo J, Wong K, Clifford T, Beutler B, Kim P Diagnostics (Basel). 2024; 14(6).

PMID: 38535006 PMC: 10969187. DOI: 10.3390/diagnostics14060585.

References
1.
Palmqvist S, Janelidze S, Quiroz Y, Zetterberg H, Lopera F, Stomrud E . Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020; 324(8):772-781. PMC: 7388060. DOI: 10.1001/jama.2020.12134. View

2.
Chen K, Gong E, Carvalho Macruz F, Xu J, Boumis A, Khalighi M . Ultra-Low-Dose F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs. Radiology. 2018; 290(3):649-656. PMC: 6394782. DOI: 10.1148/radiol.2018180940. View

3.
Nelson P, Braak H, Markesbery W . Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2008; 68(1):1-14. PMC: 2692822. DOI: 10.1097/NEN.0b013e3181919a48. View

4.
Chen H, Zhang Y, Kalra M, Lin F, Chen Y, Liao P . Low-Dose CT With a Residual Encoder-Decoder Convolutional Neural Network. IEEE Trans Med Imaging. 2017; 36(12):2524-2535. PMC: 5727581. DOI: 10.1109/TMI.2017.2715284. View

5.
Ozlen H, Binette A, Kobe T, Meyer P, Gonneaud J, St-Onge F . Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition. JAMA Neurol. 2022; 79(10):1025-1035. PMC: 9396472. DOI: 10.1001/jamaneurol.2022.2442. View